Literature DB >> 24556051

Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis.

Siddharth Singh1, Palaniappan Manickam2, Anita V Amin2, Niharika Samala2, Leo J Schouten3, Prasad G Iyer1, Tusar K Desai2.   

Abstract

BACKGROUND: The natural history of low-grade dysplasia (LGD) in patients with Barrett's esophagus (BE) is unclear.
OBJECTIVE: We performed a systematic review and meta-analysis of studies that reported the incidence of esophageal adenocarcinoma (EAC) and/or high-grade dysplasia (HGD) among patients with BE with LGD.
DESIGN: Systematic review and meta-analysis of cohort studies. PATIENTS: Patients with BE-LGD, with mean cohort follow-up ≥ 2 years. MAIN OUTCOME MEASUREMENTS: Pooled incidence rates with 95% confidence intervals (CI) of EAC and/or BE-HGD.
RESULTS: We identified 24 studies reporting on 2694 patients with BE-LGD, with 119 cases of EAC. Pooled annual incidence rates of EAC alone and EAC and/or HGD in patients with BE-LGD were 0.54% (95% CI, 0.32-0.76; 24 studies) and 1.73% (95% CI, 0.99-2.47; 17 studies). The results were stable across study setting and location and in high-quality studies. Substantial heterogeneity was observed, which could be explained by stratifying based on LGD/BE ratio as a surrogate for quality of pathology; the pooled annual incidence rates of EAC were 0.76% (95% CI, 0.44-1.09; 14 studies) for LGD/BE ratio <0.15 and 0.32% (95% CI, 0.07-0.58; 10 studies) for LGD/BE ratio >0.15. The annual rate of mortality not related to esophageal disease in patients with BE-LGD was 4.7% (95% CI, 3.2-6.2; 4 studies). LIMITATIONS: Substantial heterogeneity was observed in the overall analysis.
CONCLUSION: The incidence of EAC among patients with BE-LGD is 0.54% annually. The LGD/BE ratio appears to explain the variation observed in the reported incidence of EAC in different cohorts. Conditions not related to esophageal disease are a major cause of mortality in patients with BE-LGD, although additional studies are warranted.
Copyright © 2014 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24556051     DOI: 10.1016/j.gie.2014.01.009

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  56 in total

Review 1.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

Review 2.  Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus.

Authors:  Magnus Halland; David Katzka; Prasad G Iyer
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

Review 3.  Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease.

Authors:  Stéphane Groulx; Heather Limburg; Marion Doull; Scott Klarenbach; Harminder Singh; Brenda J Wilson; Brett Thombs
Journal:  CMAJ       Date:  2020-07-06       Impact factor: 8.262

Review 4.  Barrett's esophagus: diagnosis and management.

Authors:  Swathi Eluri; Nicholas J Shaheen
Journal:  Gastrointest Endosc       Date:  2017-01-18       Impact factor: 9.427

5.  Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry.

Authors:  Rajesh Krishnamoorthi; Jason T Lewis; Murli Krishna; Nicholas J Crews; Michele L Johnson; Ross A Dierkhising; Brenda F Ginos; Kenneth K Wang; Herbert C Wolfsen; David E Fleischer; Francisco C Ramirez; Navtej S Buttar; David A Katzka; Prasad G Iyer
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

Review 6.  Disease Progression in Barrett's Low-Grade Dysplasia With Radiofrequency Ablation Compared With Surveillance: Systematic Review and Meta-Analysis.

Authors:  Bashar J Qumseya; Sachin Wani; Sherif Gendy; Ben Harnke; Jacques J Bergman; Herbert Wolfsen
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

7.  Barrett's Esophagus With Low-Grade Dysplasia: Ablate or Wait?

Authors:  Sravanthi Parasa; Prateek Sharma
Journal:  Am J Gastroenterol       Date:  2017-01-17       Impact factor: 10.864

Review 8.  Endoscopic risk factors for neoplastic progression in patients with Barrett's oesophagus.

Authors:  Angela Bureo Gonzalez; Jacques Jghm Bergman; Roos E Pouw
Journal:  United European Gastroenterol J       Date:  2016-03-02       Impact factor: 4.623

Review 9.  Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.

Authors:  Francisco Schlottmann; Daniela Molena; Marco G Patti
Journal:  Updates Surg       Date:  2018-07-23

10.  Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.

Authors:  Aaron J Small; James L Araujo; Cadman L Leggett; Aaron H Mendelson; Anant Agarwalla; Julian A Abrams; Charles J Lightdale; Timothy C Wang; Prasad G Iyer; Kenneth K Wang; Anil K Rustgi; Gregory G Ginsberg; Kimberly A Forde; Phyllis A Gimotty; James D Lewis; Gary W Falk; Meenakshi Bewtra
Journal:  Gastroenterology       Date:  2015-04-24       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.